Clinical Trial

A Study in Advanced or Metastatic Gastrointestinal Cancers Exploring Treatment Combinations With Pelareorep and Atezolizumab

Study acronym: GOBLET
Active, Not Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This is an open-label, phase 1/2, multiple-indication platform study to explore safety, potential predictive immune-related biomarkers, and early efficacy (as measured by objective response rate \[ORR; Cohorts 1,2, 4,and 5\] and disease control rate \[DCR; Cohort 3\]) in patients with advanced or metastatic gastrointestinal (GI) tumors. Cohorts 1-4 are not randomized; however, Cohort 5 is comprised of two treatment arms to which patients are randomized in a 1:1 ratio.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-12-03.
Status change: Recruiting → Active, Not Recruiting 2026-05-18
Trial Details
NCT Number NCT07280377
Lead Sponsor Oncolytics Biotech
Collaborators: Crolll Gmbh, AIO-Studien-gGmbH
Conditions Anal Cancer Metastatic, Squamous Cell Carcinoma of the Anus Stage Unspecified, Pancreatic Cancer Metastatic, Unresectable Pancreatic Carcinoma
Enrollment 122 participants
Start Date 2021-10-27
Primary Completion 2027-07-30 (estimated)
Study Completion 2028-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-05-19